Study and detection of potential markers for predicting metastasis into lymph nodes in prostate cancer

Biomark Med. 2020 Oct;14(14):1317-1327. doi: 10.2217/bmm-2020-0372. Epub 2020 Aug 17.

Abstract

Hormone-refractory prostate carcinoma has a different cell surface protein profile than hormone-sensitive prostate carcinoma, which provides migration ability and interactions with organs/tissues. Detection and association of these proteins with lymph node metastasis via lymphadenectomy might be beneficial for patients. Gene expression analysis in hormone-refractory and hormone-sensitive commercial cancer cell lines was performed and, after co-cultivation with osteoblasts or endothelial cells, knockdown experiments followed to validate potential biomarkers. "Myeloid-associated differentiation markers, myosin 1b and phosphatidylinositol-4-phosphate-5-kinase type 1 alpha are implicated in metastasis", their knockdown altered the expression of key regulators of endothelial-mesenchymal transition, invasion, motility and migration. In primary prostate tumors, these genes could be an indicator for future metastasis into lymph nodes.

Keywords: MYADM; MYO1B; PIP5K1A; bone metastasis; lymph node metastasis; prostate cancer.

MeSH terms

  • Biomarkers, Tumor / metabolism*
  • Humans
  • Lymphatic Metastasis
  • Male
  • Prognosis
  • Prostatic Neoplasms / metabolism*
  • Prostatic Neoplasms / pathology*

Substances

  • Biomarkers, Tumor